Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD

Inclusion Criteria: * (1)Age ≥50 years and ≤80 years, regardless of gender. * (2)Patients with atrophic AMD in the macular area (geographic atrophy \>250μm, involving the foveal center); or stable non-exudative AMD patients who have undergone treatment for wet AMD or have naturally converted to non-exudative AMD (referring to patients with fibrovascular scar formation, who are unresponsive to anti-VEGF treatment, and have no macular edema on OCT and/or no fluorescein leakage on FFA), with a scar diameter not exceeding 6 PD. * (3)Best-corrected visual acuity (BCVA) of the study eye ≥5 letters and ≤34 letters (using the ETDRS visual acuity chart). * (4)If both eyes meet the criteria, the more severely affected eye will be selected; if the severity is the same in both eyes, the right eye will be designated as the study eye. * (5)The patient or their legal representative has signed a written informed consent form. Exclusion Criteria: * Ocular Diseases: * (1)Vitreous hemorrhage in the study eye within 2 months prior to screening. * (2)Presence of a scar, fibrosis, or atrophy involving the fovea in the study eye, or a peripheral scar area greater than 6 PD, indicating severe irreversible visual loss. * (3)Presence of pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage causing visual loss, rhegmatogenous retinal detachment, macular hole, or choroidal neovascularization due to any cause in the study eye. * (4)Presence of a pupillary block defect (APD…